Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609147 | 0.91 | PDE10A (0.50) | PDE10APDE4BPDE4DCHRM3PDE4A | |
| SCHEMBL1609451 | 0.90 | PDE10A (0.52) | PDE10APDE4BPDE4DCHRM3PDE4A | |
| SCHEMBL1609768 | 0.90 | PDE10A (0.49) | PDE10ARAB9APDE4BPDE4DCHRM3 | |
| SCHEMBL1610831 | 0.90 | PDE10A (0.45) | PDE10AVNN1 | |
| SCHEMBL1609715 | 0.89 | PDE10A (0.48) | PDE10APDE4BPDE4DCHRM3PDE4A | |
| SCHEMBL1609831 | 0.89 | PDE10A (0.48) | PDE10APDE4BPDE4DCHRM3PDE4A | |
| SCHEMBL1609704 | 0.89 | PDE10A (0.62) | PDE10APDE4BPDE4DCHRM3PDE4A | |
| SCHEMBL1613172 | 0.88 | PDE10A (0.47) | PDE10ARAB9APDE4BPDE4DCHRM3 | |
| SCHEMBL1609755 | 0.88 | PDE10A (0.63) | PDE10APDE4BPDE4DCHRM3PDE4A | |
| SCHEMBL1610706 | 0.87 | PDE10A (0.47) | PDE10ARAB9AL3MBTL1PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009081112-A2 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | DDT, PNPO, CBR3 | PDE10A 1704/4885RAB9A 3012/4885VNN1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.